Development of a deprescribing manual for frail older people for use in the COFRAIL study and in primary care.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Drug Safety Pub Date : 2022-09-06 eCollection Date: 2022-01-01 DOI:10.1177/20420986221122684
Nina-Kristin Mann, Sven Schmiedl, Achim Mortsiefer, Veronika Bencheva, Susanne Löscher, Manuela Ritzke, Eva Drewelow, Gregor Feldmeier, Sara Santos, Stefan Wilm, Petra A Thürmann
{"title":"Development of a deprescribing manual for frail older people for use in the COFRAIL study and in primary care.","authors":"Nina-Kristin Mann, Sven Schmiedl, Achim Mortsiefer, Veronika Bencheva, Susanne Löscher, Manuela Ritzke, Eva Drewelow, Gregor Feldmeier, Sara Santos, Stefan Wilm, Petra A Thürmann","doi":"10.1177/20420986221122684","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Many older adults are affected by multimorbidity and subsequent polypharmacy which is associated with adverse outcomes. This is especially relevant for frail older patients. Polypharmacy may be reduced via deprescribing. As part of the complex intervention in the COFRAIL study, we developed a deprescribing manual to be used by general practitioners (GPs) in family conferences, in which GPs, patients and caregivers jointly discuss treatments.</p><p><strong>Methods: </strong>We selected indications with a high prevalence in older adults in primary care (e.g. diabetes mellitus, hypertension) and conducted a literature search to identify deprescribing criteria for these indications. We additionally reviewed clinical practice guidelines. Based on the extracted information, we created a deprescribing manual which was then piloted in an expert workshop and in family conferences with volunteer patients according to the inclusion and exclusion criteria of the study protocol.</p><p><strong>Results: </strong>Initially, 13 indications/topics were selected. The literature search identified deprescribing guides, reviews and clinical trials as well as lists of potentially inappropriate medication and systematic reviews on the risk and benefits of specific drugs and drug classes in older patients. After piloting and revisions, the deprescribing manual now covers 11 indications/topics. In each chapter, patient- and medication-related deprescribing criteria, monitoring and communication strategies, and information about concerns related to the use of specific drugs in older patients are provided.</p><p><strong>Discussion: </strong>We found varying deprescribing strategies in the literature, which we consolidated in our deprescribing manual. Whether this approach leads to successful deprescribing in family conferences is being investigated in the cluster-randomised controlled COFRAIL study.</p><p><strong>Plain language summary: </strong><b>Development of a manual to help doctors to identify which medications can be withdrawn</b> Many older adults suffer from chronic diseases and take multiple medications concurrently. This can lead to side effects and other undesired events. We developed a manual to help doctors identify which medications can be withdrawn, so that they can discuss this with their patients. This manual was used in the COFRAIL study where doctors, patients and caregivers met in family conferences to discuss their preferences and decide together how future treatments should be handled. The manual contains information on common medications, symptoms and diseases in older patients such as diabetes and high blood pressure. Before the manual was used in the study, it was tested by volunteer patients and their doctors and caregivers to make sure that it is user-friendly.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/22/10.1177_20420986221122684.PMC9452796.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986221122684","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Many older adults are affected by multimorbidity and subsequent polypharmacy which is associated with adverse outcomes. This is especially relevant for frail older patients. Polypharmacy may be reduced via deprescribing. As part of the complex intervention in the COFRAIL study, we developed a deprescribing manual to be used by general practitioners (GPs) in family conferences, in which GPs, patients and caregivers jointly discuss treatments.

Methods: We selected indications with a high prevalence in older adults in primary care (e.g. diabetes mellitus, hypertension) and conducted a literature search to identify deprescribing criteria for these indications. We additionally reviewed clinical practice guidelines. Based on the extracted information, we created a deprescribing manual which was then piloted in an expert workshop and in family conferences with volunteer patients according to the inclusion and exclusion criteria of the study protocol.

Results: Initially, 13 indications/topics were selected. The literature search identified deprescribing guides, reviews and clinical trials as well as lists of potentially inappropriate medication and systematic reviews on the risk and benefits of specific drugs and drug classes in older patients. After piloting and revisions, the deprescribing manual now covers 11 indications/topics. In each chapter, patient- and medication-related deprescribing criteria, monitoring and communication strategies, and information about concerns related to the use of specific drugs in older patients are provided.

Discussion: We found varying deprescribing strategies in the literature, which we consolidated in our deprescribing manual. Whether this approach leads to successful deprescribing in family conferences is being investigated in the cluster-randomised controlled COFRAIL study.

Plain language summary: Development of a manual to help doctors to identify which medications can be withdrawn Many older adults suffer from chronic diseases and take multiple medications concurrently. This can lead to side effects and other undesired events. We developed a manual to help doctors identify which medications can be withdrawn, so that they can discuss this with their patients. This manual was used in the COFRAIL study where doctors, patients and caregivers met in family conferences to discuss their preferences and decide together how future treatments should be handled. The manual contains information on common medications, symptoms and diseases in older patients such as diabetes and high blood pressure. Before the manual was used in the study, it was tested by volunteer patients and their doctors and caregivers to make sure that it is user-friendly.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
为年老体弱者编写一份处方手册,供 COFRAIL 研究和初级保健使用。
简介许多老年人患有多种疾病,并随之使用多种药物,这与不良后果有关。这与体弱的老年患者尤为相关。可以通过取消处方来减少多重用药。作为 COFRAIL 研究中复杂干预措施的一部分,我们编写了一份去处方化手册,供全科医生(GPs)在家庭会议中使用,在家庭会议中,全科医生、患者和护理人员共同讨论治疗方法:我们选择了老年人在初级医疗中发病率较高的适应症(如糖尿病、高血压),并进行了文献检索,以确定这些适应症的去处方化标准。此外,我们还查阅了临床实践指南。根据提取的信息,我们编写了一份去处方化手册,然后根据研究方案中的纳入和排除标准,在专家研讨会和志愿患者的家庭会议上试用:最初选定了 13 个适应症/主题。通过文献检索,确定了处方指南、综述和临床试验,以及可能不适当的药物清单和关于老年患者服用特定药物和药物类别的风险和益处的系统综述。经过试点和修订,去药方手册目前涵盖 11 个适应症/专题。在每一章中,都提供了与患者和药物相关的停药标准、监控和沟通策略,以及与老年患者使用特定药物相关的关注信息:讨论:我们在文献中发现了不同的去处方化策略,并将其整合到我们的去处方化手册中。讨论:我们在文献中发现了各种不同的去处方策略,并将其整合到我们的去处方手册中。这一方法是否能在家庭会议中成功去处方,我们正在分组随机对照 COFRAIL 研究中进行调查。这可能会导致副作用和其他不良反应。我们编写了一份手册,帮助医生识别哪些药物可以停药,以便他们与患者讨论。在 COFRAIL 研究中,医生、患者和护理人员通过家庭会议讨论他们的偏好,并共同决定如何处理未来的治疗。手册包含老年患者常见药物、症状和疾病(如糖尿病和高血压)的相关信息。在研究中使用该手册之前,志愿者患者及其医生和护理人员对手册进行了测试,以确保手册便于使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
期刊最新文献
Assessing potential risk factors for metamizole-induced leukopenia Impact of different doses of esketamine on the incidence of hypotension in propofol-based sedation for colonoscopy: a randomized controlled trial Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 2020 Characterizing medication safety incidents in surgical patients: a retrospective cross-sectional analysis of incident reports
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1